Insufficient scRNA-seq data for expression of RWDD3 at single-cell level.
Insufficient scRNA-seq data for expression of RWDD3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 760.67 | 1445 / 1445 | 99% | 3.60 | 182 / 183 |
brain | 100% | 801.53 | 2642 / 2642 | 99% | 3.84 | 701 / 705 |
breast | 100% | 916.70 | 459 / 459 | 99% | 3.83 | 1109 / 1118 |
thymus | 100% | 1062.68 | 653 / 653 | 98% | 3.89 | 594 / 605 |
prostate | 100% | 1059.58 | 245 / 245 | 98% | 3.83 | 491 / 502 |
ovary | 100% | 898.97 | 180 / 180 | 97% | 2.97 | 418 / 430 |
pancreas | 100% | 761.55 | 328 / 328 | 97% | 3.20 | 173 / 178 |
uterus | 100% | 1037.45 | 170 / 170 | 96% | 3.22 | 442 / 459 |
bladder | 100% | 1004.14 | 21 / 21 | 96% | 3.32 | 485 / 504 |
stomach | 100% | 746.27 | 359 / 359 | 96% | 2.84 | 274 / 286 |
intestine | 100% | 969.98 | 966 / 966 | 95% | 2.55 | 499 / 527 |
lung | 98% | 582.99 | 565 / 578 | 95% | 2.69 | 1099 / 1155 |
kidney | 100% | 841.19 | 89 / 89 | 91% | 2.76 | 819 / 901 |
liver | 100% | 902.84 | 226 / 226 | 91% | 2.58 | 369 / 406 |
skin | 100% | 730.32 | 1806 / 1809 | 88% | 3.06 | 417 / 472 |
adrenal gland | 100% | 938.13 | 258 / 258 | 87% | 1.94 | 200 / 230 |
adipose | 100% | 782.29 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 1057.67 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.12 | 1 / 1 |
blood vessel | 100% | 760.65 | 1331 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 756.08 | 858 / 861 | 0% | 0 | 0 / 0 |
muscle | 100% | 519.22 | 800 / 803 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 87% | 1.86 | 39 / 45 |
lymph node | 0% | 0 | 0 / 0 | 86% | 2.59 | 25 / 29 |
eye | 0% | 0 | 0 / 0 | 70% | 2.20 | 56 / 80 |
peripheral blood | 47% | 252.16 | 436 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0033235 | Biological process | positive regulation of protein sumoylation |
GO_0032088 | Biological process | negative regulation of NF-kappaB transcription factor activity |
GO_1902073 | Biological process | positive regulation of hypoxia-inducible factor-1alpha signaling pathway |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005515 | Molecular function | protein binding |
Gene name | RWDD3 |
Protein name | RWD domain-containing protein 3 (RWD domain-containing sumoylation enhancer) (RSUME) |
Synonyms | RSUME |
Description | FUNCTION: Enhancer of SUMO conjugation. Via its interaction with UBE2I/UBC9, increases SUMO conjugation to proteins by promoting the binding of E1 and E2 enzymes, thioester linkage between SUMO and UBE2I/UBC9 and transfer of SUMO to specific target proteins which include HIF1A, PIAS, NFKBIA, NR3C1 and TOP1. Isoform 1 and isoform 2 positively regulate the NF-kappa-B signaling pathway by enhancing the sumoylation of NF-kappa-B inhibitor alpha (NFKBIA), promoting its stabilization which consequently leads to an increased inhibition of NF-kappa-B transcriptional activity. Isoform 1 and isoform 2 negatively regulate the hypoxia-inducible factor-1 alpha (HIF1A) signaling pathway by increasing the sumoylation of HIF1A, promoting its stabilization, transcriptional activity and the expression of its target gene VEGFA during hypoxia. Isoform 2 promotes the sumoylation and transcriptional activity of the glucocorticoid receptor NR3C1 and enhances the interaction of SUMO1 and NR3C1 with UBE2I/UBC9. Has no effect on ubiquitination. . |
Accessions | ENST00000263893.10 [Q9Y3V2-2] Q9Y3V2 ENST00000370202.5 [Q9Y3V2-1] |